Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician–Patient Real-World Clinical Data Analysis

[1] Barocas DA(2015)Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study Lancet Lond Engl 386 743-800

[2] Globe DR(2012)Surveillance and treatment of non-muscle-invasive bladder cancer in the USA Adv Urol 2012 421709-3227

[3] Colayco DC(2011)Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis Cell Death Dis. 2 e124-477

[4] Onyenwenyi A(2013)Recurrence of high-risk bladder cancer: a population-based analysis Cancer 119 3219-1029

[5] Bruno AS(2006)Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol. 49 466-475

[6] Bramley TJ(2016)Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline J Urol 196 1021-461

[7] Ahmad I(2013)Bladder cancer J Natl Compr Cancer Netw JNCCN 11 446-1104

[8] Patel R(2017)EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016 Eur Urol. 71 447-450

[9] Liu Y(2014)The health economics of bladder cancer: an updated review of the published literature PharmacoEconomics. 32 1093-1444

[10] Singh LB(2006)What is the clinical utility of genetic testing? Genet Med 8 448-756

[1] Barocas DA(2015)Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study Lancet Lond Engl 386 743-800

[2] Globe DR(2012)Surveillance and treatment of non-muscle-invasive bladder cancer in the USA Adv Urol 2012 421709-3227

[3] Colayco DC(2011)Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis Cell Death Dis. 2 e124-477

[4] Onyenwenyi A(2013)Recurrence of high-risk bladder cancer: a population-based analysis Cancer 119 3219-1029

[5] Bruno AS(2006)Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol. 49 466-475

[6] Bramley TJ(2016)Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline J Urol 196 1021-461

[7] Ahmad I(2013)Bladder cancer J Natl Compr Cancer Netw JNCCN 11 446-1104

[8] Patel R(2017)EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016 Eur Urol. 71 447-450

[9] Liu Y(2014)The health economics of bladder cancer: an updated review of the published literature PharmacoEconomics. 32 1093-1444

[10] Singh LB(2006)What is the clinical utility of genetic testing? Genet Med 8 448-756